Ha INTRAARTICULAR INJECTION: THERAPEUTIC AND ECONOMIC CONSIDERATIONS by Henrotin, Yves
HA INTRAARTICULAR INJECTION: 
THERAPEUTIC AND ECONOMIC 
CONSIDERATIONS
Osteoarthritis























Modified Clegg et al. Eur J Orthop Surg Traumatol, 2013
IA
Acetaminophen

















































“Viscosupplementation is the process that restores the normal
rheological environment in the synovial fluid, synovial
tissue…and reestablishes the protection, lubrication, shock
absorption and barrier effects.”








•Viscoinduction ensures that the effect is 
maintained for several months despite the short 
half-life of intra-articular HA 
–stimulate endogenous HA synthesis 
–Other biological effects (block IL-1 activity)
Gigante A. and Callegari L. Rheumat. Intern. 2010; 31 (4): 427-444.
Gosh P. and Guidolin D. Seminars Arthr. Rheum. 2002; 32 (1): 10-37.
Viscoinduction
IAHA has a moderate effect on knee OA 
symptoms OARSI meta-analysis
(Zhang et al, 2010)
ES Pain ES Function
Acetominophen 0.14 (0.05,0.23) 0.09 (-0.03,0.22)
Diacerein 0.24 (0.08, 0.39) 0.14 (0.03, 0.26)
NSAIDs 0.29 (0.22,0.35) -
Aerobic 0.52 (0.34; 0.70) 0.46 (0.25, 067)
Glucosamine
Sulfate
0.58 (0,30, 0.87) 0.07 (-0.08,0,021)
IAHA 0.60 (0.37, 0,83) 0.61 (0.35,0.87)
Chondroitin sulfate 0.75 (0.50, 1.01) -
IAHA effect size is superior to  NSAIDS with less GI adverse events
HA improves pain and function in knee OA
*All Studies
ES < 0.2 = None
ES 0.2 – 05 = Weak
ES 0.5 – 08 = Moderate













Zhang W. et al. Osteoarthritis & Cartilage 2010; 18: 473-475.
AH vs corticostéroïdes
Comparing with intra-articular corticosteroids, 
benefits last generally longer! 
8 RCT : ES = 0,21 vs Placebo à 3 mois
Knee: HA in recent guidelines
Society Guidelines
ACR (2012) American College of 
Rheumatology
« Conditionnally recommended to not 
use »
AAOS (2013) American Association of 
Orthropaedic Surgeons
« Not recommended »
NICE (2014) National Institute for Health
and Clinical Excellence
« Do not offer intra-articular injection 
of hyaluronan for the management of 
OA »
OARSI (2014) Osteoarthritis Research
Society International
« Uncertain » let to the appreciation of 
the physician
« …iatrogenesis due to the overuse of NSAIDS, paracetamol and corticosteroids









Coll2-1 and Coll2-1NO2: 










 Specific of degradated cartilage
 Measure cartilage catabolism
Coll2-1
BIOVISCO study: Study design






1NO2, s C2C, sCOMP, 
sCS-846, sCPII, CTX-II
Henrotin Y et al. Journal of Orthopaedic Research
19 FEB 2013
BIOVISCO study
An open label observational prospective study
Conrozier et al, J Orthp Res, 2012; Henrotin et al, J Orthp Res,2013.
D1 
(after the last injection)
90 days
(after the last injection)
p-Value
D1 vs D90
sColl2-1 (nM) 140.34(882.44-285.32) 128.41 (85.6-241.34) 0.05*
sColl2-1NO2 (nM) 0.400 (0.050-1.010) 0.370 (0.14-0.870) 0.025*
uCTX-II (ng/nmolcreat) 392.7 (90.0-816.4) 306.0 (90-1123.9) 0.02*
sPIICP (ng/ml) 817.9 (131.4-1848.6) 874.8.3 (326.4-1435.0) 0.41
sC2C (ng/ml) 223.6 (99.4-329) 209.5 (135.9-291.7) 0.11
sCOMP (U/L) 10.9 (6.0-20.2) 10.5 (6.0-20.0) 0.82
sCS846 (ng/ml) 99.8 (45.9-172.3) 102.2 (53.0-190) 0.38
sHA (ng/ml) 34.1 (15.4-211) 33.3 (9.5-230.1) 0.38
 45 patients with unilateral symptomatic tibiofemoral and/or patellofemoral OA
 3-weekly intraarticular injection of hyalan G20 (Synvisc®)
 Follow-up D1, D30 and D90 after the last injection
The EPIKART study
 A 6-month prospective, randomized, double blind, 
controlled study
 A single injection of KARTILAGE®Cross or  saline 
solution
 PRIMARY OUTCOME
– the variation of Coll2-1 in serum between 
inclusion visit (D-10) and D90 (3 months after 
injection)
KARTILAGE®Cross
- 2.2 ml (16 mg HA/ml) 
Reticulated
- Biofermentation
- Mannitol (35 mg/g of gel)
Inclusion criteria
 Men or women aged between 45 and 
80 years old
 With symptomatic femoro-tibial OA
 VAS > 40 mm



















































• IAHA is efficient and well tolerated
• IAHA is a cost-effectiveness treatment
• The efficacy is moderate on pain and function
• The efficacy is superior to NSAIDS at 1-month
• Prolonged effect compared to corticosteroids
• Indication and efficacy should be evaluated at 
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